SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The ...

Merck KGaA pays $85M for global rights to Abbisko's pimicotinib, a CSF-1R inhibitor for TGCT that competes with Daiichi ...

Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects ...

Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...

CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...

After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

Appeals court upholds J&J win blocking Mylan's generic version of schizophrenia drug Invega Trinza, protecting patent for ...

Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision.

DBV Technologies could get $306M for peanut allergy patch; Eisai sells Pariet rights in China; Palatin reports UC trial data; ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...